ELTX Key Statistics, Chart & Performance
The current stock price of ELTX is 8.24 USD. In the past month the price increased by 1.85%. In the past year, price increased by 34.42%.
ELTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.72 | 396.12B | ||
| AMGN | AMGEN INC | 15.09 | 177.76B | ||
| GILD | GILEAD SCIENCES INC | 14.73 | 149.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 27.06 | 119.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.8 | 84.19B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 783.14 | 52.76B | ||
| INSM | INSMED INC | N/A | 36.31B | ||
| NTRA | NATERA INC | N/A | 33.06B | ||
| BIIB | BIOGEN INC | 11.11 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.6 | 21.14B | ||
| INCY | INCYTE CORP | 16.5 | 20.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.76B |
Related stock screener links
About ELTX
Company Profile
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Company Info
ELICIO THERAPEUTICS INC
451 D Street, 5Th Floor
Boston MASSACHUSETTS US
Employees: 32
Phone: 18572090050
ELICIO THERAPEUTICS INC / ELTX FAQ
Can you describe the business of ELICIO THERAPEUTICS INC?
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2021-02-05. The firm is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The firm provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Can you provide the latest stock price for ELICIO THERAPEUTICS INC?
The current stock price of ELTX is 8.24 USD. The price decreased by -0.72% in the last trading session.
What is the dividend status of ELICIO THERAPEUTICS INC?
ELTX does not pay a dividend.
How is the ChartMill rating for ELICIO THERAPEUTICS INC?
ELTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is ELICIO THERAPEUTICS INC (ELTX) stock traded?
ELTX stock is listed on the Nasdaq exchange.
What do analysts say about ELICIO THERAPEUTICS INC (ELTX) stock?
8 analysts have analysed ELTX and the average price target is 15.81 USD. This implies a price increase of 91.87% is expected in the next year compared to the current price of 8.24.
ELTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ELTX. When comparing the yearly performance of all stocks, ELTX turns out to be only a medium performer in the overall market: it outperformed 53.41% of all stocks.
ELTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ELTX. ELTX may be in some trouble as it scores bad on both profitability and health.
ELTX Financial Highlights
Over the last trailing twelve months ELTX reported a non-GAAP Earnings per Share(EPS) of -3.15. The EPS increased by 36.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -162.13% | ||
| ROE | -1201.7% | ||
| Debt/Equity | 2.55 |
ELTX Forecast & Estimates
8 analysts have analysed ELTX and the average price target is 15.81 USD. This implies a price increase of 91.87% is expected in the next year compared to the current price of 8.24.